文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

心理意象对减少酒精使用障碍和酒精性肝损伤患者的酒精相关伤害的影响:MIRAGE 随机试点试验结果。

Mental Imagery to Reduce Alcohol-related harm in patients with alcohol use disorder and alcohol-related liver damaGE: the MIRAGE randomised pilot trial results.

机构信息

Faculty of Health, University of Plymouth, Plymouth, UK

South West Liver Unit, University Hospitals Plymouth NHS Trust, Plymouth, UK.

出版信息

BMJ Open Gastroenterol. 2024 Jan 29;11(1):e001267. doi: 10.1136/bmjgast-2023-001267.


DOI:10.1136/bmjgast-2023-001267
PMID:38286518
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10870787/
Abstract

OBJECTIVE: The healthcare burden of alcohol-related liver disease (ARLD) is increasing. ARLD and alcohol use disorder (AUD) is best managed by reduction or cessation of alcohol use, but effective treatments are lacking. We tested whether people with ARLD and AUD admitted to hospital could be recruited to and retained in a trial of Functional Imagery Training (FIT), a psychological therapy that uses mental imagery to reduce alcohol craving. We conducted a multicentre randomised pilot trial of treatment as usual (TAU) versus FIT+TAU in people admitted to hospital with ARLD and AUD. DESIGN: Participants were randomised to TAU (a single session of brief intervention) or FIT+TAU (TAU with one hospital-based FIT session then eight telephone sessions over 6 months). Pilot outcomes included recruitment rate and retention at day 180. Secondary outcomes included fidelity of FIT delivery, alcohol use, and severity of alcohol dependence. RESULTS: Fifty-four participants (mean age 49; 63% male) were recruited and randomised, 28 to TAU and 26 to FIT+TAU. The retention rate at day 180 was 43%. FIT was delivered adequately by most alcohol nurses. 50% of intervention participants completed FIT sessions 1 and 2. There were no differences in alcohol use or severity of alcohol dependence between treatment groups at day 180. CONCLUSION: Participants with ARLD and AUD could be recruited to a trial of FIT versus FIT+TAU. However, retention at day 180 was suboptimal. Before conducting a definitive trial of FIT in this patient group, modifications in the intervention and recruitment/retention strategy must be tested. TRIAL REGISTRATION NUMBER: ISRCTN41353774.

摘要

目的:与酒精相关的肝脏疾病(ARLD)的医疗负担正在增加。减少或停止饮酒是治疗 ARLD 和酒精使用障碍(AUD)的最佳方法,但目前缺乏有效的治疗方法。我们测试了患有 ARLD 和 AUD 的人是否可以被招募并留在一项功能性意象训练(FIT)试验中,这是一种使用心理意象来减少酒精渴望的心理治疗。我们在因 ARLD 和 AUD 住院的人群中进行了一项关于常规治疗(TAU)与 FIT+TAU 的多中心随机试验。 设计:参与者被随机分配到 TAU(一次简短干预)或 FIT+TAU(TAU 加一次医院基础 FIT 治疗,然后在 6 个月内进行 8 次电话治疗)。试验的主要结果包括招募率和第 180 天的保留率。次要结果包括 FIT 交付的保真度、饮酒量和酒精依赖严重程度。 结果:共招募并随机分配了 54 名参与者(平均年龄 49 岁;63%为男性),28 名接受 TAU,26 名接受 FIT+TAU。第 180 天的保留率为 43%。大多数酒精护士都能充分提供 FIT。50%的干预参与者完成了前 2 次 FIT 治疗。在第 180 天,两组的饮酒量和酒精依赖严重程度没有差异。 结论:患有 ARLD 和 AUD 的患者可以被招募参加 FIT 与 FIT+TAU 的试验。然而,第 180 天的保留率并不理想。在对该患者群体进行 FIT 的确定性试验之前,必须对干预措施和招募/保留策略进行修改。 试验注册号:ISRCTN41353774。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa0e/10870787/8cfd83dd905c/bmjgast-2023-001267f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa0e/10870787/8cfd83dd905c/bmjgast-2023-001267f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa0e/10870787/8cfd83dd905c/bmjgast-2023-001267f01.jpg

相似文献

[1]
Mental Imagery to Reduce Alcohol-related harm in patients with alcohol use disorder and alcohol-related liver damaGE: the MIRAGE randomised pilot trial results.

BMJ Open Gastroenterol. 2024-1-29

[2]
Mental Imagery to Reduce Alcohol-related harm in patients with alcohol dependence and alcohol-related liver damaGE: the MIRAGE pilot trial protocol.

BMJ Open. 2022-5-18

[3]
Preoperative behavioural intervention to reduce drinking before elective orthopaedic surgery: the PRE-OP BIRDS feasibility RCT.

Health Technol Assess. 2020-3

[4]
Superiority and cost-effectiveness of Individual Placement and Support versus standard employment support for people with alcohol and drug dependence: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial.

EClinicalMedicine. 2024-1-18

[5]
Development of severe alcohol related liver disease over four decades in Iceland: impact of increased access and use of alcohol.

Scand J Gastroenterol. 2023

[6]
Behavioural activation therapy for post-stroke depression: the BEADS feasibility RCT.

Health Technol Assess. 2019-9

[7]
Universal screening for alcohol misuse in acute medical admissions is feasible and identifies patients at high risk of liver disease.

J Hepatol. 2017-7-27

[8]
Smoking Cessation Intervention for severe Mental Ill Health Trial (SCIMITAR): a pilot randomised control trial of the clinical effectiveness and cost-effectiveness of a bespoke smoking cessation service.

Health Technol Assess. 2015-3

[9]
Improving alcohol treatment engagement using integrated behavioral interventions in alcohol-associated liver disease: A randomized pilot trial.

Hepatol Commun. 2023-10-1

[10]
Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.

Lancet Psychiatry. 2020-9

引用本文的文献

[1]
Treatment of alcohol use disorder in alcohol-associated liver disease: A meta-analysis.

Hepatol Commun. 2025-4-30

[2]
Positive mental imagery, emotion regulation and depressive symptoms in individuals with alcohol use disorder.

Front Psychiatry. 2025-4-8

本文引用的文献

[1]
Deaths from alcohol-related liver disease in the UK: an escalating tragedy.

Lancet. 2023-2-11

[2]
Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis.

Clin Gastroenterol Hepatol. 2023-8

[3]
The Liverpool alcohol-related liver disease algorithm identifies twice as many emergency admissions compared to standard methods when applied to Hospital Episode Statistics for England.

Aliment Pharmacol Ther. 2023-2

[4]
Mental Imagery to Reduce Alcohol-related harm in patients with alcohol dependence and alcohol-related liver damaGE: the MIRAGE pilot trial protocol.

BMJ Open. 2022-5-18

[5]
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.

Drugs. 2022-2

[6]
Social robots as treatment agents: Pilot randomized controlled trial to deliver a behavior change intervention.

Internet Interv. 2020-5-7

[7]
Reducing variation in hospital mortality for alcohol-related liver disease in North West England.

Aliment Pharmacol Ther. 2020-5-22

[8]
The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

Lancet Gastroenterol Hepatol. 2020-1-22

[9]
Advances in the science and treatment of alcohol use disorder.

Sci Adv. 2019-9-25

[10]
Natural history of histologically proven alcohol-related liver disease: A systematic review.

J Hepatol. 2019-6-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索